The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw or Maxilla in a Large Population of Cancer Patients Treated with Intravenous Bisphosphonates.

Ao, Hoff; Toth, B.; Altundag, K.; Johnson, M.; Warneke, C.; Nooka, A.; Sayegh, G.; Guarneri, V.; Desrouleaux, K.; Cui, J.; Adamus, A.; Gn, Gagel Rf And Hortobagyi

Links

[hdl.handle.net]

Tools

Export citation

Search in Google Scholar

The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw or Maxilla in a Large Population of Cancer Patients Treated with Intravenous Bisphosphonates.

Journal article published in 2008 by Hoff Ao, B. Toth, K. Altundag, M. Johnson, C. Warneke, A. Nooka, G. Sayegh, V. Guarneri, K. Desrouleaux, J. Cui, A. Adamus, Gagel Rf And Hortobagyi Gn

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

Abstract

INTRODUCTION: Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. The incidence and risk factors associated with this disorder have not been clearly defined. MATERIALS AND METHODS: We conducted a retrospective analysis of 4019 patients treated with intravenous bisphosphonates between 1996 and 2004. Our goals were to estimate the frequency, understand the clinical presentation, and identify risk factors associated with ONJ development. RESULTS: Sixteen of 1338 patients with breast cancer (1.2%) and 13 of 548 patients with multiple myeloma (2.4%) developed ONJ. The median dose and duration of treatment with pamidronate or zoledronic acid were significantly higher in patients with ONJ (p